Physician profile
John Y Koo
NPI 1245289594
$2,991,923.94
in general payments reported to CMS, 2019-2025
32 companies · $421K in 2025
The $421K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547K · 2020: $223K · 2021: $313K · 2022: $512K · 2023: $555K · 2024: $421K · 2025: $421K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Travel and Lodging: $169K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $92K · Consulting Fee: $63K · Food and Beverage: $33K · Honoraria: $305 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,038,792.15 |
| Travel and Lodging | $168,602.80 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $92,240.00 |
| Consulting Fee | $63,027.12 |
| Food and Beverage | $33,387.06 |
| Honoraria | $305.30 |
| Education | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $569,948.82 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Abbvie INC. | $424,660.56 | 2019-2025 | |
| Amgen INC. | $294,247.33 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $238,298.27 | 2019-2025 | Ilumya |
| Pfizer INC. | $210,363.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $200,852.14 | 2019-2025 | Dupixent |
| Ucb, INC. | $181,348.49 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $131,654.29 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $118,603.73 | 2019-2025 | Tremfya |
| Celgene Corporation | $117,975.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $105,660.31 | 2020-2025 | Sotyktu |
| Leo Pharma INC. | $91,271.79 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $81,392.43 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $57,774.57 | 2019-2025 | |
| Galderma Laboratories, L.P. | $45,357.79 | 2020-2025 | Nemluvio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $34,641.83 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31,028.86 | 2019-2025 | Siliq, Duobrii |
| Sanofi-Aventis U.S. LLC | $26,221.12 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $8,228.77 | 2023-2025 | Zoryve |
| Epi Health, LLC | $5,300.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,643.05 | 2019-2024 | Spevigo |
| Intuitive Surgical, INC. | $4,559.11 | 2021-2022 | |
| Janssen Global Services, LLC | $2,110.75 | 2022 | |
| Hikma Pharmaceuticals USA | $2,000.00 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $1,125.19 | 2019-2024 | Dupixent |
| Celltrion, INC. | $1,000.00 | 2022-2023 | |
| Almirall LLC | $600.00 | 2019 | |
| Incyte Corporation | $592.44 | 2021-2025 | Opzelura, Opzelura |
| Eli Lilly and Company | $212.97 | 2024-2025 | Ebglyss |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.73 | 2025 | Siliq |
| Lemaitre Vascular, INC. | $85.81 | 2019 | |
| Sandoz INC. | $49.39 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Koo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.